Therefore, while individuals with type 2 diabetes exhibit considerable resistance to the insulinotropic effects of exogenous GIP administration and there is no direct correlation between obesity and GIP in humans, the comparative advantages of inhibiting versus activating GIP receptor signaling must be evaluated in future therapeutic applications of GIP or its analogs. Here, GIP is linked to Obesity.